United Therapeutics (UTHR) EPS (Basic) Growth (3y) (2012 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) EPS (Basic) Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.87 Bn | 624.11 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 440.91 Bn | 434.35 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 366.10 Bn | 358.96 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 267.00 Bn | 259.31 Bn | 11.24 Bn | 14.72% |
| 5 | Pfizer | 159.23 Bn | 147.53 Bn | 10.94 Bn | -28.08% |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | -36.03% |
| 7 | Revolution Medicines | 44.24 Bn | 44.24 Bn | - | - |
| 8 | Incyte | 25.34 Bn | 20.80 Bn | 1.57 Bn | 47.44% |
| 9 | United Therapeutics | 21.48 Bn | 18.82 Bn | 683.80 Mn | 12.25% |
| 10 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 13.47% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.25% |
| Mar 31, 2026 | 6.69% |
| Dec 31, 2025 | 41.49% |
| Sep 30, 2025 | 13.71% |
| Jun 30, 2025 | 39.00% |
| Mar 31, 2025 | 10.58% |
| Dec 31, 2024 | 38.69% |
| Sep 30, 2024 | 24.13% |
| Jun 30, 2024 | 17.58% |
| Mar 31, 2024 | 117.44% |
| Dec 31, 2023 | 27.55% |
| Sep 30, 2023 | 13.95% |
| Jun 30, 2023 | 31.53% |
| Mar 31, 2023 | 18.38% |
| Dec 31, 2022 | 34.21% |
| Sep 30, 2022 | 20.37% |
| Jun 30, 2022 | -18.28% |
| Mar 31, 2022 | 35.16% |
| Dec 31, 2021 | 18.52% |
| Sep 30, 2021 | 14.05% |